Biodexa Announces 1-for-8 Reverse ADS Split Effective October 26
Summary
Biodexa announced a 1-for-8 reverse ADS split effective October 26, 2026, changing the ADS ratio from 1:50 to 1:400 ordinary shares. The move appears aimed at lifting the ADS price to maintain NASDAQ listing compliance amid ongoing financial distress.
Key Events · Corporate Governance and Compliance · BDRX
-
1-for-8 Reverse ADS Split Announced
ADS ratio changes from 1 ADS = 50 ordinary shares to 1 ADS = 400 ordinary shares, effective on or about October 26, 2026. Every 8 old ADSs (CUSIP 59564R872) will be exchanged for 1 new ADS (CUSIP 59564R864).
-
Mandatory Exchange with No Fractional ADSs
ADS holders must surrender their ADSs for cancellation and exchange. No fractional ADSs will be allocated; aggregate fractions will be sold and net proceeds distributed to entitled holders. JPMorgan Chase Bank, N.A. will arrange the exchange.
-
Ordinary Shares Unaffected
The ratio change applies only to ADSs, not to the underlying ordinary shares. The company's ordinary share count and nominal value remain unchanged.
-
Listing Compliance Context
The reverse ADS split follows a 1-for-10,000 reverse stock split approved on July 29, 2026, and comes amid a going concern warning with only £3.23 million in cash at June 30, 2026. The move is likely intended to raise the ADS price to maintain NASDAQ Capital Market listing requirements.
Analysis · BDRX · Life Sciences
Biodexa is changing its ADS ratio from 1 ADS representing 50 ordinary shares to 1 ADS representing 400 ordinary shares, effective on or about October 26, 2026. For ADS holders, this is equivalent to a 1-for-8 reverse ADS split — every 8 old ADSs will be exchanged for 1 new ADS. The ordinary shares themselves are unaffected. This is a mandatory exchange with no fractional ADSs allocated; any fractional interests will be sold and net proceeds distributed to holders. The change comes amid severe financial distress: the company reported only £3.23 million in cash at June 30, 2026, a going concern warning, and has been repeatedly raising capital through warrant inducements and resale registrations. The reverse ADS split is likely intended to boost the ADS price to maintain NASDAQ listing compliance, but it does not change the underlying equity value or the company's cash position.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 31% of the 1656 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $360.4K. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.